# Lansoprazole

## Takepron Intravenous 30mg

| 藥物代碼 | ITAK |
| :--- | :--- |
| 適應症 | As an alternative to oral therapy when oral intake is not appropriate for GERD in patients with esophagitis &/or severe symptoms of reflux & for healing of gastric ulcers associated with NSAID therapy. |
| 副作用 | Headache, abdominal pain, diarrhea, flatulence, nausea/vomiting, constipation. Abnormal hepatic function tests, hyperbilirubinemia, increased serum alkaline phosphatase, increased serum ALT, increased serum AST. |
| 禁忌 | Hypersensitivity to Lansoprazole. |
| 藥物保存方式 | 室溫 |
| 用法用量 | 30 mg IV once or twice daily infusion over 30 minutes. |
| 肝功能異常 | 需 調 整 劑 量  嚴重肝功能不良之病患需小心使用。 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | Human data suggest low risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity\(Mother\) 無\(很少\)資料 - 避免使用\(母體\) |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【D5W】 可選 仿單建議  【N/S】 可選 仿單建議 |
| IVP 用法建議 | N/A |
| IVD 用法建議 | Intravenous infusion over 30 minutes. |
| 注意事項 | 注射劑給藥建議途徑：僅可靜脈輸注方式投予。 配製藥品: 1. 加入5 mL 0.9%氯化鈉注射液或5%葡萄糖注射液至藥瓶內，並輕輕混合至粉末溶解。 2. 以50 mL的0.9%氯化鈉注射液或5%葡萄糖注射液稀釋配製液。 3. 混合液配製完成後不可存放，應立即使用。 |

## Takepron OD 30mg

| 藥物代碼 | OTAK |
| :--- | :--- |
| 適應症 | Gastric & duodenal ulcer, reflux esophagitis & Zollinger-Ellison syndrome. In combination of antibiotics to treat H. pylori related peptic ulcer. |
| 副作用 | Hypersensitivity reactions. Rarely, hematological changes; severe hepatic dysfunction with jaundice & enzyme changes; Lyell syndrome, Stevens-Johnson syndrome, interstitial pneumonia.Gastrointestinal: Abdominal pain \(up to 5% \), Constipation \(1% to 5% \), Diarrhea \(up to 7.4% \), Nausea \(1.3% to 3% \)Neurologic: HeadacheOther: Fatigue |
| 禁忌 | NA |
| 藥物保存方式 | 室溫 |
| 用法用量 | OD tab Gastric & duodenal ulcer, Zollinger-Ellison syndrome 30 mg once daily for 6 weeks in gastric ulcer & 8 weeks in duodenal ulcer. Reflux esophagitis 30 mg once daily for 8 weeks. Maintenance: 15 mg once daily. May adjust to 30 mg once daily is desired result is not achieved. Adjunct to eradication of H. pylori associated with gastric ulcer or duodenal ulcer lansoprazole 30 mg bid, amoxycillin 750 mg \(potency\) bid & clarithromycin 200 mg \(potency\) bid for 7 days. |
| 肝功能異常 | 需 調 整 劑 量  Severe impairment \(Child-Pugh class C\): 15 mg once daily. |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 可能安全 |
| 孕期用藥建議 | Human data suggest low risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

